Evaluation of contemporary platinum-doublet chemotherapy-modified dose and schedules-Reference-Cited by-同舟云学术

Evaluation of contemporary platinum-doublet chemotherapy-modified dose and schedules

Published:2013-10 Issue:5 Volume:2 Page:329-332
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Sangal Ashish¹,Weiss Glen J²

Affiliation:

1. Cancer Treatment Centers of America, 14200 Celebrate Life Way, Goodyear, AZ 85338, USA

2. CRAB-Clinical Trials Consortium, Seattle, WA, USA.

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt.13.38

Reference16 articles.

1. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

2. DeVitaVT Jr. Principles of cancer management: chemotherapy. In:Cancer: Principles and Practice of Oncology (5th edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA,333–347 (1997).

3. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

4. Randomized, Multicenter, Open-Label Phase II Study of Gemcitabine plus Single-Dose Versus Split-Dose Carboplatin in the Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

5. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metals;Side Effects of Drugs Annual;2014